Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125454101 | 12545410 | 1 | I | 20090618 | 20121127 | 20160711 | 20160711 | EXP | CA-PFIZER INC-1511375 | PFIZER | 42.00 | YR | F | Y | 72.20000 | KG | 20160711 | OT | GB | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125454101 | 12545410 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | 840 MG, (DOSE LEVEL: 6 AUC), EVERY THREE WEEKS | 4272 | MG | Y | 76517 | 840 | MG | SOLUTION FOR INJECTION | Q3W | |||
| 125454101 | 12545410 | 2 | SS | BEVACIZUMAB | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | 1050 MG, (DOSE LEVEL: 15 MG/KG), EVERY THREE WEEKS | 5340 | MG | Y | 0 | 1050 | MG | Q3W | ||||
| 125454101 | 12545410 | 3 | SS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | 129 MG (DOSE LEVEL: 75 MG/M2), EVERY THREE WEEKS | Y | 0 | 129 | MG | Q3W | ||||||
| 125454101 | 12545410 | 4 | SS | DOCETAXEL. | DOCETAXEL | 1 | UNK | Y | 0 | ||||||||||
| 125454101 | 12545410 | 5 | SS | TRASTUZUMAB | TRASTUZUMAB | 1 | Intravenous (not otherwise specified) | 420 MG, (DOSE LEVEL: 6MG/KG), EVERY THREE WEEKS | 2136 | MG | 0 | 420 | MG | Q3W | |||||
| 125454101 | 12545410 | 6 | C | NORVASC | AMLODIPINE BESYLATE | 1 | 10 MG | 0 | 10 | MG | |||||||||
| 125454101 | 12545410 | 7 | C | PANTOLOC /01263204/ | PANTOPRAZOLE SODIUM | 1 | 80 MG | 0 | 80 | MG | |||||||||
| 125454101 | 12545410 | 8 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | 25 MG | 0 | 25 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125454101 | 12545410 | 1 | HER-2 positive breast cancer |
| 125454101 | 12545410 | 2 | HER-2 positive breast cancer |
| 125454101 | 12545410 | 3 | HER-2 positive breast cancer |
| 125454101 | 12545410 | 5 | HER-2 positive breast cancer |
| 125454101 | 12545410 | 6 | Product used for unknown indication |
| 125454101 | 12545410 | 7 | Product used for unknown indication |
| 125454101 | 12545410 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125454101 | 12545410 | DS |
| 125454101 | 12545410 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125454101 | 12545410 | Encephalopathy | |
| 125454101 | 12545410 | Febrile neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125454101 | 12545410 | 1 | 20090318 | 20090723 | 0 | |
| 125454101 | 12545410 | 2 | 20090318 | 20090723 | 0 | |
| 125454101 | 12545410 | 3 | 20090318 | 0 | ||
| 125454101 | 12545410 | 4 | 20090723 | 0 | ||
| 125454101 | 12545410 | 5 | 20090318 | 20090723 | 0 | |
| 125454101 | 12545410 | 6 | 20090419 | 0 | ||
| 125454101 | 12545410 | 7 | 20090428 | 0 | ||
| 125454101 | 12545410 | 8 | 20090419 | 0 |